Volitionrx Ltd (VNRX) Stock Forecast Oct. 13, 2026
Analysis updated on Oct. 13, 2026 (UTC) · Alpha · vs marketSwitch to Total · NYSE
Volitionrx Ltd (VNRX) stock forecast summary
Our AI ranks Volitionrx Ltd outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Volitionrx Ltd is a small-cap company with a market capitalization of $3M. It ranks number 15 by market capitalization among the 15 In Vitro & In Vivo Diagnostic Substances issuers in our coverage with a current forecast. Its Current Ratio of 0.30x is the lowest of the 15 peers that report one.
A per-ticker accuracy statistic for VNRX is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.2%, buy ≥ +0.5%, sell < -0.6%, strong sell < -1.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-14 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, VNRX included.
Follow VNRX freeVNRX price chart and AI forecast
How VNRX ranks among 4004 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Volitionrx Ltd (VNRX) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the In Vitro & In Vivo Diagnostic Substances peers listed below that report each metric.
Reported net income does not reconcile with earnings per share and the share count, so net-income-based ratios are withheld.
Valuation & Market
| Metric | VNRX | Rank |
|---|---|---|
| Market Cap | $3M | 15/15 |
| EPS | $-1.01 | – |
| Revenue/Share | $0.18 | – |
| FCF/Share | $-1.43 | – |
Profitability & Margins
| Metric | VNRX | Rank |
|---|---|---|
| Operating Margin | -790.2% | 10/14 |
| EBT Margin | -790.2% | 10/14 |
Financial Health
| Metric | VNRX | Rank |
|---|---|---|
| Current Ratio | 0.30x | 15/15 |
| Interest Coverage | -35.5x | 10/14 |
| Working Capital | -$9M | 15/15 |
Cash Flow
| Metric | VNRX | Rank |
|---|---|---|
| Operating Cash Flow | -$20M | 11/16 |
| Free Cash Flow | -$20M | 6/10 |
| Capital Spending | -$20K | 1/10 |
| FCF/Sales | -796.8% | 7/10 |
| CapEx/Sales | 0.9% | 10/10 |
Operational Efficiency
| Metric | VNRX | Rank |
|---|---|---|
| Asset Turnover | 0.30x | 7/12 |
| Receivables Turnover | 8.9x | 2/11 |
| Fixed Assets Turnover | 0.7x | 9/12 |
| Days Sales Outstanding | 41 days | 10/11 |
Income Statement
| Metric | VNRX | Rank |
|---|---|---|
| Total Revenue | $2M | 9/12 |
| Operating Income | -$19M | 10/15 |
| R&D Expense | $9M | 10/16 |
| SG&A Expense | $18M | 8/12 |
Dividend & Shareholder Information
| Metric | VNRX | Rank |
|---|---|---|
| Shares Outstanding | 14M | – |
| EPS Growth | -496.6% | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $4M | |
| Cash & Short-term Investments | $3M | |
| Accounts Receivable | $280K | |
| Total Liabilities | $42M | |
| Short-term Debt | $10M |
VNRX quarterly financials and insider trading
Volitionrx Ltd (VNRX) industry peers
Companies classified under the same SEC industry code as Volitionrx Ltd (In Vitro & In Vivo Diagnostic Substances): 17 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| VNRX Volitionrx Ltd | ▼ | $3M |
| IDXX Idexx Laboratories Inc /De | ▼ | $40.99B |
| LNTH Lantheus Holdings, Inc. | ▼ | $6.53B |
| NEOG Neogen Corp | ▲ | $2.56B |
| CLDX Celldex Therapeutics, Inc. | ▲ | $2.22B |
| NTLA Intellia Therapeutics, Inc. | ▲ | $1.67B |
| QDEL Quidelortho Corp | ▶ | $967M |
| ACHV Achieve Life Sciences, Inc. | ▶ | $720M |
| TKNO Alpha Teknova, Inc. | ▲ | $441M |
| MYGN Myriad Genetics Inc | ▲ | $390M |
| ICCC Immucell Corp /De/ | ▲ | $98M |
| IMDX Insight Molecular Diagnostics Inc. | ▲ | $98M |
| AWHL Aspira Women's Health Inc. | ▲ | $12M |
| BMRA Biomerica Inc | ▲ | $8M |
| CDIO Cardio Diagnostics Holdings, Inc. | ▶ | $5M |
| QCLS Q/C Technologies, Inc. | ▼ | N/A |
| TRIB Trinity Biotech Plc | ▼ | N/A |
Where VNRX sits on the market map
Volitionrx Ltd (VNRX) stock news
Loading...
Volitionrx Ltd (VNRX) stock forecast FAQ
What is the Volitionrx Ltd (VNRX) stock forecast?
Our AI ranks Volitionrx Ltd outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Volitionrx Ltd stock predictions?
A per-ticker accuracy statistic for VNRX is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Volitionrx Ltd forecasts updated?
Volitionrx Ltd forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 13, 2026.
Which companies are Volitionrx Ltd's industry peers?
17 issuers in our coverage, VNRX included, share the SEC industry code In Vitro & In Vivo Diagnostic Substances. The largest are: Idexx Laboratories Inc /De (IDXX), Lantheus Holdings, Inc. (LNTH), Neogen Corp (NEOG), Celldex Therapeutics, Inc. (CLDX), Intellia Therapeutics, Inc. (NTLA), Quidelortho Corp (QDEL).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.